EUCODIS Bioscience Release: Two Industry Executives Appointed to Realigned Advisory Board
Published: Sep 02, 2010
With its current members, EUCODIS Bioscience’s Advisory Board will focus on providing guidance and advice in the areas of strategy, market and organization, strengthening the skills and experience of EUCODIS Bioscience’s management team.
“I am extremely pleased to welcome two distinguished executives of the biotechnology industry to our Advisory Board”, said Thomas Fischer, CEO EUCODIS Bioscience. “Dr. Rozzell as a successful founder and entrepreneur in the enzyme industry, and Dr. Bethke with entrepreneurial mindset and his track record in biotechnology manufacturing and operations, bring to EUCODIS Bioscience a wealth of hands-on experience and operational knowledge. Having these seasoned executives on our Advisory Board will be a tremendous asset to the Company as our customer base is growing rapidly. We will continue to expand our portfolio, and are aggressively addressing new business opportunities in the pharmaceutical, bioproducts, cosmetics, and other industries.”
Dr. David Rozzell is President and CEO of Solidus Biosciences, a company providing research and analytical services to the pharmaceutical and cosmetics industry, enhancing their development productivity. Prior to joining Solidus as CEO, he was the Founder and CEO of enzyme developer BioCatalytics, which he grew to a leader in its field until the company was successfully sold to Codexis in 2007. Before founding BioCatalytics, Dr. Rozzell was President and COO of Exogene.
Dr. Ulf Bethke is Chief Operating Officer of Miltenyi Biotec, one of Germany’s most successful biotechnology companies. Before joining Miltenyi Biotec in 1994, he was responsible for the development and production of therapeutic monoclonal antibodies at Biotest, a German pharmaceutical company.
Dr. Thomas Moser is Managing Partner at Pontis Capital, an Austrian venture capital company. He has 10 years of experience as an investment manager, overseeing the whole investment life-cycle, from deal acquisition through active management of portfolio companies to financing and implementation of the exit strategy.
Harald Schuerz is CEO of Wiener Wachstumsfonds, an Austrian venture capital fund focusing on innovative, fast growing companies. Before joining Athena, he held executive positions at leading Austrian banks where he was responsible for venture capital investments and international financing.
About EUCODIS Bioscience
EUCODIS Bioscience provides enzymes to the chemical, health care, and other industries, and offers custom-engineering and custom-manufacturing services.
Customers use EUCODIS Bioscience’ enzymes and services to make their manufacturing processes more efficient and cleaner and to introduce products with superior properties. The Company’s technology of in vivo-recombination is a proven tool for the directed evolution of enzymes that perform to customers’ specific requirements.
Enzymes are proteins that catalyze highly specific chemical reactions, offering a safer, cleaner, and competitive alternative to traditional chemistry. They are at the center of industrial, or “white” biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.
Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.
For more information, please visit www.eucodisbioscience.com
Company contact EUCODIS Bioscience:
Media contact EUCODIS Bioscience:
Frank Butschbacher Investor Relations & Communications www.butschbacher.net +43-650-7844940